SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Neurological Disorders
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lanctôt, K. L.
Right arrow Articles by Herrmann, N.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Therapy for Alzheimer's disease: how effective are current treatments?

Krista L. Lanctôt

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, krista.lanctot{at}sunnybrook.ca

Ryan D. Rajaram

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Nathan Herrmann

Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Available symptomatic therapies for the treatment of Alzheimer's disease (AD) have been based on known neurotransmitter dysfunctions associated with the illness. The second-generation cholinesterase inhibitors and the N-methyl D-aspartate receptor antagonist memantine have been widely prescribed and studied. Meta-analyses of these therapies were reviewed, focusing on effectiveness and tolerability. Although many of the meta-analyses demonstrate statistically significant improvements, some question if these benefits are sufficient to justify their current widespread and protracted use. This has spurred the development of new disease-modifying therapies that aim to have a greater impact on this debilitating illness.

Key Words: Alzheimer's disease • cholinesterase inhibitors • meta-analysis • donepezil • galantamine • rivastigmine • memantine • tacrine • beta amyloid • tau protein

Therapeutic Advances in Neurological Disorders, Vol. 2, No. 3, 163-180 (2009)
DOI: 10.1177/1756285609102724
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement